Organisation paid for research Program year 2025 Source: CMS Open Payments

Deerbrook Medical Associates

Neither a doctor nor a teaching hospital

Research payments

$640,535

195 payments

Through program year 2025, Deerbrook Medical Associates is reported as receiving $640,535 in research payments, across 195 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $109,551 17
2024 Research $58,444 20
2023 Research $31,686 13
2022 Research $37,193 18
2021 Research $72,446 36
2020 Research $134,217 47
2019 Research $196,999 44

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $564,442 188 payments
  2. Novartis Pharmaceuticals Corporation $65,573 2 payments
  3. Eli Lilly and Company $8,012 4 payments
  4. Sanofi US Services Inc. $2,507 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) $81,635 10 payments
  2. M15-554 $78,148 17 payments
  3. A Randomized, Double-Blind, Parallel-Group, Multicenter Study of Secukinumab to Compare 300 MG and 150 MG at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During An Initial 16 We $65,573 2 payments
  4. Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) $65,193 18 payments
  5. M15-572 $59,337 21 payments
  6. M13-549 $41,594 18 payments
  7. A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) $37,482 19 payments
  8. M19-130 $29,897 10 payments
  9. M13-545 $20,824 9 payments
  10. A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus $19,919 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record